Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

KEVIN MICHAEL DONNELLY

Allopathic & Osteopathic Physicians Dermatology

NPI
1366805517
CMS profile
2412990
Location
WESTERVILLE, OH

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$2,251.10

108 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $2,145.84 106
Education $105.26 2

By paying entity

PY2023 · entire year · sorted by reported total

Page 2 of 3; records 51–100 of 108 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

KEVIN MICHAEL DONNELLY

NPI 1366805517 · CMS profile ID 2412990

Allopathic & Osteopathic Physicians / Dermatology

WESTERVILLE, OH

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 3; records 51–100 of 108 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1366805517?year=2023&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
KEVIN MICHAEL DONNELLY, NPI 1366805517, CMS profile ID 2412990. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 108 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1366805517?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). KEVIN MICHAEL DONNELLY, NPI 1366805517, CMS profile ID 2412990. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 108 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1366805517?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
KEVIN MICHAEL DONNELLY, NPI 1366805517, CMS profile ID 2412990, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 3; records 51–100 of 108 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1366805517?year=2023&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

108 matching records · $2,251.10 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 108 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 108.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Lilly USA, LLC $14.7806/29/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031872583 CMS
E.R. Squibb & Sons, L.L.C. $0.6006/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015880141 CMS
E.R. Squibb & Sons, L.L.C. $11.7506/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015880145 CMS
GENZYME CORPORATION $22.4206/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049707755 CMS
Regeneron Healthcare Solutions, Inc. $14.8206/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999156485 CMS
AbbVie Inc. $22.3406/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996725451 CMS
E.R. Squibb & Sons, L.L.C. $24.3706/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015880121 CMS
AbbVie Inc. $16.3806/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996725445 CMS
Janssen Biotech, Inc. $16.1506/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988398487 CMS
Dermavant Sciences, Inc. $109.9706/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991178615 CMS
PFIZER INC. $16.5406/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050582009 CMS
Arcutis Biotherapeutics, Inc. $13.2406/02/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044765565 CMS
Lilly USA, LLC $15.2805/30/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031872585 CMS
Dermavant Sciences, Inc. $11.3705/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991178611 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $17.4805/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997120577 CMS
AbbVie Inc. $24.2805/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996725439 CMS
Dermavant Sciences, Inc. $17.4505/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991178607 CMS
Incyte Corporation $20.8305/04/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044523389 CMS
Janssen Biotech, Inc. $22.7905/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988398497 CMS
MAYNE PHARMA COMMERCIAL LLC $26.9705/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1060810275 CMS
Novartis Pharmaceuticals Corporation $20.1504/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991601783 CMS
AbbVie Inc. $13.1904/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996725435 CMS
AbbVie Inc. $26.6104/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996725431 CMS
Lilly USA, LLC $19.5604/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031746011 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $20.6404/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997064733 CMS
E.R. Squibb & Sons, L.L.C. $24.6904/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015880061 CMS
GENZYME CORPORATION $19.8504/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049707711 CMS
Arcutis Biotherapeutics, Inc. $13.5304/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044765577 CMS
Dermavant Sciences, Inc. $21.1104/04/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991178603 CMS
Janssen Biotech, Inc. $89.9904/04/2023 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988398477 CMS
Janssen Biotech, Inc. $16.9004/04/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988398507 CMS
AbbVie Inc. $17.1103/30/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996725425 CMS
Regeneron Healthcare Solutions, Inc. $23.3303/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999156481 CMS
AbbVie Inc. $17.2303/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996725421 CMS
E.R. Squibb & Sons, L.L.C. $24.1003/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015880049 CMS
Incyte Corporation $19.4203/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044523307 CMS
GENZYME CORPORATION $18.3103/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049707667 CMS
PFIZER INC. $15.2703/13/2023 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049571057 CMS
AbbVie Inc. $22.9103/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996725415 CMS
Dermavant Sciences, Inc. $94.1403/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991178599 CMS
LEO Pharma Inc. $15.9103/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1053466591 CMS
Regeneron Healthcare Solutions, Inc. $21.4803/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999156477 CMS
AbbVie Inc. $12.4703/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996725411 CMS
Janssen Biotech, Inc. $17.1003/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988398455 CMS
AbbVie Inc. $18.0602/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996725407 CMS
Amgen Inc. $15.5002/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1020617423 CMS
PFIZER INC. $16.4902/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049373991 CMS
MAYNE PHARMA COMMERCIAL LLC $23.1002/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1060810277 CMS
E.R. Squibb & Sons, L.L.C. $21.8302/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015880021 CMS
Janssen Biotech, Inc. $21.0502/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988398447 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,142.91 10
PY2020 $140.11 2
PY2021 $452.60 27
PY2022 $2,026.76 81
PY2023 $2,251.10 108
PY2024 $2,532.22 123
PY2025 $5,789.32 157

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $136,398.69 127
PY2024 Recipient $7,172.96 11
PY2024 Principal investigator $201,965.23 79

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

127 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Incyte Corporation $1,171.00 12/11/2025 Non-covered Recipient Entity
CENTRICITY RESEARCH AVENTIV RESEARCH DUBLIN
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240515240
Principal investigator 1 Incyte Corporation $288.00 12/11/2025 Non-covered Recipient Entity
CENTRICITY RESEARCH AVENTIV RESEARCH DUBLIN
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240515244
Principal investigator 1 GlaxoSmithKline, LLC. $144.90 11/25/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC DBA CENTRICITY RESEARCH
LONG-TERM EXTENSION STUDY (ATDVANCE) TO EVALUATE THE SAFETY AND EFFICA No dispute reported 06/30/2026 1192107123
Principal investigator 1 Incyte Corporation $700.00 11/25/2025 Non-covered Recipient Entity
CENTRICITY RESEARCH AVENTIV RESEARCH DUBLIN
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240515208
Principal investigator 1 Incyte Corporation $1,161.00 11/25/2025 Non-covered Recipient Entity
CENTRICITY RESEARCH AVENTIV RESEARCH DUBLIN
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240515212
Principal investigator 1 Incyte Corporation $800.00 11/25/2025 Non-covered Recipient Entity
CENTRICITY RESEARCH AVENTIV RESEARCH DUBLIN
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240515216
Principal investigator 1 Incyte Corporation $3,183.00 11/25/2025 Non-covered Recipient Entity
CENTRICITY RESEARCH AVENTIV RESEARCH DUBLIN
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240515220
Principal investigator 1 Incyte Corporation $375.00 11/25/2025 Non-covered Recipient Entity
CENTRICITY RESEARCH AVENTIV RESEARCH DUBLIN
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240515227
Principal investigator 1 Incyte Corporation $7,250.00 11/25/2025 Non-covered Recipient Entity
CENTRICITY RESEARCH AVENTIV RESEARCH DUBLIN
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240515231
Principal investigator 1 GlaxoSmithKline, LLC. $144.90 11/20/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC DBA CENTRICITY RESEARCH
LONG-TERM EXTENSION STUDY (ATDVANCE) TO EVALUATE THE SAFETY AND EFFICA No dispute reported 06/30/2026 1192104900
Principal investigator 1 GlaxoSmithKline, LLC. $448.50 11/20/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC DBA CENTRICITY RESEARCH
LONG-TERM EXTENSION STUDY (ATDVANCE) TO EVALUATE THE SAFETY AND EFFICA No dispute reported 06/30/2026 1192162855
Principal investigator 1 Incyte Corporation $90.00 11/14/2025 Non-covered Recipient Entity
CENTRICITY RESEARCH AVENTIV RESEARCH DUBLIN
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240515224
Principal investigator 1 Incyte Corporation $6,383.00 11/07/2025 Non-covered Recipient Entity
CENTRICITY RESEARCH AVENTIV RESEARCH DUBLIN
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240515235
Principal investigator 1 Incyte Corporation $351.00 10/29/2025 Non-covered Recipient Entity
CENTRICITY RESEARCH AVENTIV RESEARCH DUBLIN
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240515173
Principal investigator 1 Incyte Corporation $273.00 10/29/2025 Non-covered Recipient Entity
CENTRICITY RESEARCH AVENTIV RESEARCH DUBLIN
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240515177
Principal investigator 1 Incyte Corporation $1,000.00 10/29/2025 Non-covered Recipient Entity
CENTRICITY RESEARCH AVENTIV RESEARCH DUBLIN
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240515180
Principal investigator 1 Incyte Corporation $1,000.00 10/29/2025 Non-covered Recipient Entity
CENTRICITY RESEARCH AVENTIV RESEARCH DUBLIN
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240515185
Principal investigator 1 Incyte Corporation $500.00 10/29/2025 Non-covered Recipient Entity
CENTRICITY RESEARCH AVENTIV RESEARCH DUBLIN
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240515188
Principal investigator 1 Incyte Corporation $120.00 10/29/2025 Non-covered Recipient Entity
CENTRICITY RESEARCH AVENTIV RESEARCH DUBLIN
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240515204
Principal investigator 1 SANOFI US SERVICES INC. $2,278.00 10/20/2025 Non-covered Recipient Entity
Cr Services Acquisition Us Llc Centricity Research
A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel Group, Proof-of-concept Study Assessing the Efficacy and Safety of Amlitelimab in Adult Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1226089239
Principal investigator 1 GlaxoSmithKline, LLC. $1,750.00 10/17/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC DBA CENTRICITY RESEARCH
A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, PLACEBO CONTROLL No dispute reported 06/30/2026 1192100417
Principal investigator 1 GlaxoSmithKline, LLC. $2,000.00 10/17/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC DBA CENTRICITY RESEARCH
A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, PLACEBO CONTROLL No dispute reported 06/30/2026 1192104094
Principal investigator 1 GlaxoSmithKline, LLC. $1,000.00 10/17/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC DBA CENTRICITY RESEARCH
A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, PLACEBO CONTROLL No dispute reported 06/30/2026 1192106535
Principal investigator 1 GlaxoSmithKline, LLC. $800.00 10/17/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC DBA CENTRICITY RESEARCH
A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, PLACEBO CONTROLL No dispute reported 06/30/2026 1192107086
Principal investigator 1 Incyte Corporation $393.00 10/03/2025 Non-covered Recipient Entity
CENTRICITY RESEARCH AVENTIV RESEARCH DUBLIN
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240515192
Principal investigator 1 Incyte Corporation $890.00 10/03/2025 Non-covered Recipient Entity
CENTRICITY RESEARCH AVENTIV RESEARCH DUBLIN
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240515196
Principal investigator 1 Incyte Corporation $768.00 10/03/2025 Non-covered Recipient Entity
CENTRICITY RESEARCH AVENTIV RESEARCH DUBLIN
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240515200
Principal investigator 1 GlaxoSmithKline, LLC. $4,807.92 08/29/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC DBA CENTRICITY RESEARCH
LONG-TERM EXTENSION STUDY (ATDVANCE) TO EVALUATE THE SAFETY AND EFFICA No dispute reported 06/30/2026 1192107117
Principal investigator 1 Incyte Corporation $1,056.00 08/26/2025 Non-covered Recipient Entity
CENTRICITY RESEARCH AVENTIV RESEARCH DUBLIN
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240515170
Principal investigator 1 GlaxoSmithKline, LLC. $400.20 08/12/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC DBA CENTRICITY RESEARCH
A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, PLACEBO CONTROLL No dispute reported 06/30/2026 1192101595
Principal investigator 1 Incyte Corporation $576.00 07/31/2025 Non-covered Recipient Entity
CENTRICITY RESEARCH AVENTIV RESEARCH DUBLIN
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240515161
Principal investigator 1 Incyte Corporation $829.79 07/31/2025 Non-covered Recipient Entity
CENTRICITY RESEARCH AVENTIV RESEARCH DUBLIN
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240515166
Principal investigator 1 GlaxoSmithKline, LLC. $318.78 07/24/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC DBA CENTRICITY RESEARCH
LONG-TERM EXTENSION STUDY (ATDVANCE) TO EVALUATE THE SAFETY AND EFFICA No dispute reported 06/30/2026 1192104444
Principal investigator 1 GlaxoSmithKline, LLC. $23.76 06/24/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC DBA CENTRICITY RESEARCH
LONG-TERM EXTENSION STUDY (ATDVANCE) TO EVALUATE THE SAFETY AND EFFICA No dispute reported 06/30/2026 1192104099
Principal investigator 1 GlaxoSmithKline, LLC. $48.30 06/24/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC DBA CENTRICITY RESEARCH
LONG-TERM EXTENSION STUDY (ATDVANCE) TO EVALUATE THE SAFETY AND EFFICA No dispute reported 06/30/2026 1192104106
Principal investigator 1 GlaxoSmithKline, LLC. $144.90 06/24/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC DBA CENTRICITY RESEARCH
LONG-TERM EXTENSION STUDY (ATDVANCE) TO EVALUATE THE SAFETY AND EFFICA No dispute reported 06/30/2026 1192105687
Principal investigator 1 GlaxoSmithKline, LLC. $60.00 06/24/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC DBA CENTRICITY RESEARCH
LONG-TERM EXTENSION STUDY (ATDVANCE) TO EVALUATE THE SAFETY AND EFFICA No dispute reported 06/30/2026 1192110474
Principal investigator 1 Incyte Corporation $3,750.00 06/24/2025 Non-covered Recipient Entity
CENTRICITY RESEARCH AVENTIV RESEARCH DUBLIN
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240515132
Principal investigator 1 Incyte Corporation $2,775.00 06/24/2025 Non-covered Recipient Entity
CENTRICITY RESEARCH AVENTIV RESEARCH DUBLIN
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240515138
Principal investigator 1 Incyte Corporation $890.00 06/24/2025 Non-covered Recipient Entity
CENTRICITY RESEARCH AVENTIV RESEARCH DUBLIN
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240515143
Principal investigator 1 Incyte Corporation $2,500.00 06/24/2025 Non-covered Recipient Entity
CENTRICITY RESEARCH AVENTIV RESEARCH DUBLIN
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240515149
Principal investigator 1 Incyte Corporation $2,736.88 06/24/2025 Non-covered Recipient Entity
CENTRICITY RESEARCH AVENTIV RESEARCH DUBLIN
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240515153
Principal investigator 1 Incyte Corporation $14,000.00 06/24/2025 Non-covered Recipient Entity
CENTRICITY RESEARCH AVENTIV RESEARCH DUBLIN
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240515157
Principal investigator 1 GlaxoSmithKline, LLC. $60.00 06/23/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC DBA CENTRICITY RESEARCH
LONG-TERM EXTENSION STUDY (ATDVANCE) TO EVALUATE THE SAFETY AND EFFICA No dispute reported 06/30/2026 1192100404
Principal investigator 1 GlaxoSmithKline, LLC. $48.30 06/23/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC DBA CENTRICITY RESEARCH
LONG-TERM EXTENSION STUDY (ATDVANCE) TO EVALUATE THE SAFETY AND EFFICA No dispute reported 06/30/2026 1192101423
Principal investigator 1 GlaxoSmithKline, LLC. $300.00 06/23/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC DBA CENTRICITY RESEARCH
LONG-TERM EXTENSION STUDY (ATDVANCE) TO EVALUATE THE SAFETY AND EFFICA No dispute reported 06/30/2026 1192101455
Principal investigator 1 GlaxoSmithKline, LLC. $144.90 06/23/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC DBA CENTRICITY RESEARCH
LONG-TERM EXTENSION STUDY (ATDVANCE) TO EVALUATE THE SAFETY AND EFFICA No dispute reported 06/30/2026 1192101547
Principal investigator 1 GlaxoSmithKline, LLC. $1,854.72 06/23/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC DBA CENTRICITY RESEARCH
LONG-TERM EXTENSION STUDY (ATDVANCE) TO EVALUATE THE SAFETY AND EFFICA No dispute reported 06/30/2026 1192101553
Principal investigator 1 GlaxoSmithKline, LLC. $844.56 06/23/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC DBA CENTRICITY RESEARCH
LONG-TERM EXTENSION STUDY (ATDVANCE) TO EVALUATE THE SAFETY AND EFFICA No dispute reported 06/30/2026 1192101585
Principal investigator 1 GlaxoSmithKline, LLC. $300.00 06/23/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC DBA CENTRICITY RESEARCH
LONG-TERM EXTENSION STUDY (ATDVANCE) TO EVALUATE THE SAFETY AND EFFICA No dispute reported 06/30/2026 1192104438
Principal investigator 1 GlaxoSmithKline, LLC. $23.76 06/23/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC DBA CENTRICITY RESEARCH
LONG-TERM EXTENSION STUDY (ATDVANCE) TO EVALUATE THE SAFETY AND EFFICA No dispute reported 06/30/2026 1192104882
Principal investigator 1 GlaxoSmithKline, LLC. $44.05 06/23/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC DBA CENTRICITY RESEARCH
LONG-TERM EXTENSION STUDY (ATDVANCE) TO EVALUATE THE SAFETY AND EFFICA No dispute reported 06/30/2026 1192104887
Principal investigator 1 GlaxoSmithKline, LLC. $375.00 06/23/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC DBA CENTRICITY RESEARCH
A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, PLACEBO CONTROLL No dispute reported 06/30/2026 1192105641
Principal investigator 1 GlaxoSmithKline, LLC. $44.05 06/23/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC DBA CENTRICITY RESEARCH
LONG-TERM EXTENSION STUDY (ATDVANCE) TO EVALUATE THE SAFETY AND EFFICA No dispute reported 06/30/2026 1192105653
Principal investigator 1 GlaxoSmithKline, LLC. $300.00 06/23/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC DBA CENTRICITY RESEARCH
LONG-TERM EXTENSION STUDY (ATDVANCE) TO EVALUATE THE SAFETY AND EFFICA No dispute reported 06/30/2026 1192105678
Principal investigator 1 GlaxoSmithKline, LLC. $300.00 06/23/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC DBA CENTRICITY RESEARCH
LONG-TERM EXTENSION STUDY (ATDVANCE) TO EVALUATE THE SAFETY AND EFFICA No dispute reported 06/30/2026 1192106531
Principal investigator 1 GlaxoSmithKline, LLC. $700.00 06/23/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC DBA CENTRICITY RESEARCH
A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, PLACEBO CONTROLL No dispute reported 06/30/2026 1192107079
Principal investigator 1 GlaxoSmithKline, LLC. $144.90 06/23/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC DBA CENTRICITY RESEARCH
LONG-TERM EXTENSION STUDY (ATDVANCE) TO EVALUATE THE SAFETY AND EFFICA No dispute reported 06/30/2026 1192107095
Principal investigator 1 GlaxoSmithKline, LLC. $144.90 06/23/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC DBA CENTRICITY RESEARCH
LONG-TERM EXTENSION STUDY (ATDVANCE) TO EVALUATE THE SAFETY AND EFFICA No dispute reported 06/30/2026 1192110446
Principal investigator 1 GlaxoSmithKline, LLC. $48.30 06/23/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC DBA CENTRICITY RESEARCH
LONG-TERM EXTENSION STUDY (ATDVANCE) TO EVALUATE THE SAFETY AND EFFICA No dispute reported 06/30/2026 1192110458
Principal investigator 1 SANOFI US SERVICES INC. $384.00 06/16/2025 Non-covered Recipient Entity
Cr Services Acquisition Us Llc
A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel Group, Proof-of-concept Study Assessing the Efficacy and Safety of Amlitelimab in Adult Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1226080702
Principal investigator 1 SANOFI US SERVICES INC. $96.00 06/16/2025 Non-covered Recipient Entity
Cr Services Acquisition Us Llc
A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel Group, Proof-of-concept Study Assessing the Efficacy and Safety of Amlitelimab in Adult Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1226080706
Principal investigator 1 GlaxoSmithKline, LLC. $48.30 06/12/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC DBA CENTRICITY RESEARCH
LONG-TERM EXTENSION STUDY (ATDVANCE) TO EVALUATE THE SAFETY AND EFFICA No dispute reported 06/30/2026 1192101466
Principal investigator 1 GlaxoSmithKline, LLC. $48.30 06/12/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC DBA CENTRICITY RESEARCH
LONG-TERM EXTENSION STUDY (ATDVANCE) TO EVALUATE THE SAFETY AND EFFICA No dispute reported 06/30/2026 1192162852
Principal investigator 1 GlaxoSmithKline, LLC. $144.90 06/10/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC DBA CENTRICITY RESEARCH
LONG-TERM EXTENSION STUDY (ATDVANCE) TO EVALUATE THE SAFETY AND EFFICA No dispute reported 06/30/2026 1192101429
Principal investigator 1 GlaxoSmithKline, LLC. $144.90 06/10/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC DBA CENTRICITY RESEARCH
LONG-TERM EXTENSION STUDY (ATDVANCE) TO EVALUATE THE SAFETY AND EFFICA No dispute reported 06/30/2026 1192104450
Principal investigator 1 GlaxoSmithKline, LLC. $48.30 06/10/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC DBA CENTRICITY RESEARCH
LONG-TERM EXTENSION STUDY (ATDVANCE) TO EVALUATE THE SAFETY AND EFFICA No dispute reported 06/30/2026 1192104894
Principal investigator 1 SANOFI US SERVICES INC. $1,895.00 06/09/2025 Non-covered Recipient Entity
Cr Services Acquisition Us Llc
A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel Group, Proof-of-concept Study Assessing the Efficacy and Safety of Amlitelimab in Adult Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1226080694
Principal investigator 1 SANOFI US SERVICES INC. $315.00 06/09/2025 Non-covered Recipient Entity
Cr Services Acquisition Us Llc
A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel Group, Proof-of-concept Study Assessing the Efficacy and Safety of Amlitelimab in Adult Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1226080698
Principal investigator 1 GlaxoSmithKline, LLC. $590.64 05/29/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC DBA CENTRICITY RESEARCH
A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, PLACEBO CONTROLL No dispute reported 06/30/2026 1192100397
Principal investigator 1 GlaxoSmithKline, LLC. $60.00 05/29/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC DBA CENTRICITY RESEARCH
A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, PLACEBO CONTROLL No dispute reported 06/30/2026 1192106549
Principal investigator 1 GlaxoSmithKline, LLC. $115.92 05/29/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC DBA CENTRICITY RESEARCH
A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, PLACEBO CONTROLL No dispute reported 06/30/2026 1192107111
Principal investigator 1 GlaxoSmithKline, LLC. $300.00 05/27/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC DBA CENTRICITY RESEARCH
A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, PLACEBO CONTROLL No dispute reported 06/30/2026 1192164622
Principal investigator 1 GlaxoSmithKline, LLC. $3,015.30 05/26/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC DBA CENTRICITY RESEARCH
LONG-TERM EXTENSION STUDY (ATDVANCE) TO EVALUATE THE SAFETY AND EFFICA No dispute reported 06/30/2026 1192104425
Principal investigator 1 GlaxoSmithKline, LLC. $231.84 05/13/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC DBA CENTRICITY RESEARCH
A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, PLACEBO CONTROLL No dispute reported 06/30/2026 1192106555
Principal investigator 1 GlaxoSmithKline, LLC. $120.00 05/13/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC DBA CENTRICITY RESEARCH
A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, PLACEBO CONTROLL No dispute reported 06/30/2026 1192162843
Principal investigator 1 GlaxoSmithKline, LLC. $514.74 05/13/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC DBA CENTRICITY RESEARCH
A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, PLACEBO CONTROLL No dispute reported 06/30/2026 1192162860
Principal investigator 1 GlaxoSmithKline, LLC. $1,495.92 04/30/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC DBA CENTRICITY RESEARCH
LONG-TERM EXTENSION STUDY (ATDVANCE) TO EVALUATE THE SAFETY AND EFFICA No dispute reported 06/30/2026 1192104133
Principal investigator 1 GlaxoSmithKline, LLC. $23.76 04/30/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC DBA CENTRICITY RESEARCH
LONG-TERM EXTENSION STUDY (ATDVANCE) TO EVALUATE THE SAFETY AND EFFICA No dispute reported 06/30/2026 1192164618
Principal investigator 1 GlaxoSmithKline, LLC. $172.50 04/28/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC DBA CENTRICITY RESEARCH
A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, PLACEBO CONTROLL No dispute reported 06/30/2026 1192101441
Principal investigator 1 GlaxoSmithKline, LLC. $345.00 04/28/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC DBA CENTRICITY RESEARCH
A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, PLACEBO CONTROLL No dispute reported 06/30/2026 1192101447
Principal investigator 1 GlaxoSmithKline, LLC. $67.81 04/28/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC DBA CENTRICITY RESEARCH
LONG-TERM EXTENSION STUDY (ATDVANCE) TO EVALUATE THE SAFETY AND EFFICA No dispute reported 06/30/2026 1192101578
Principal investigator 1 GlaxoSmithKline, LLC. $345.00 04/28/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC DBA CENTRICITY RESEARCH
A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, PLACEBO CONTROLL No dispute reported 06/30/2026 1192104112
Principal investigator 1 GlaxoSmithKline, LLC. $67.81 04/28/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC DBA CENTRICITY RESEARCH
LONG-TERM EXTENSION STUDY (ATDVANCE) TO EVALUATE THE SAFETY AND EFFICA No dispute reported 06/30/2026 1192104414
Principal investigator 1 GlaxoSmithKline, LLC. $3,230.58 04/28/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC DBA CENTRICITY RESEARCH
A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, PLACEBO CONTROLL No dispute reported 06/30/2026 1192104911
Principal investigator 1 GlaxoSmithKline, LLC. $3,334.08 04/28/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC DBA CENTRICITY RESEARCH
LONG-TERM EXTENSION STUDY (ATDVANCE) TO EVALUATE THE SAFETY AND EFFICA No dispute reported 06/30/2026 1192105674
Principal investigator 1 GlaxoSmithKline, LLC. $67.81 04/28/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC DBA CENTRICITY RESEARCH
LONG-TERM EXTENSION STUDY (ATDVANCE) TO EVALUATE THE SAFETY AND EFFICA No dispute reported 06/30/2026 1192106517
Principal investigator 1 GlaxoSmithKline, LLC. $144.90 04/28/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC DBA CENTRICITY RESEARCH
LONG-TERM EXTENSION STUDY (ATDVANCE) TO EVALUATE THE SAFETY AND EFFICA No dispute reported 06/30/2026 1192106525
Principal investigator 1 GlaxoSmithKline, LLC. $345.00 04/28/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC DBA CENTRICITY RESEARCH
A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, PLACEBO CONTROLL No dispute reported 06/30/2026 1192107103
Principal investigator 1 GlaxoSmithKline, LLC. $144.90 04/28/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC DBA CENTRICITY RESEARCH
LONG-TERM EXTENSION STUDY (ATDVANCE) TO EVALUATE THE SAFETY AND EFFICA No dispute reported 06/30/2026 1192162839
Principal investigator 1 GlaxoSmithKline, LLC. $517.50 04/28/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC DBA CENTRICITY RESEARCH
A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, PLACEBO CONTROLL No dispute reported 06/30/2026 1192164614
Principal investigator 1 SANOFI US SERVICES INC. $7,876.00 04/07/2025 Non-covered Recipient Entity
Cr Services Acquisition Us Llc
A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel Group, Proof-of-concept Study Assessing the Efficacy and Safety of Amlitelimab in Adult Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1226080669
Principal investigator 1 GlaxoSmithKline, LLC. $60.00 04/04/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC DBA CENTRICITY RESEARCH
LONG-TERM EXTENSION STUDY (ATDVANCE) TO EVALUATE THE SAFETY AND EFFICA No dispute reported 06/30/2026 1192107131
Principal investigator 1 SANOFI US SERVICES INC. $2,954.00 04/02/2025 Non-covered Recipient Entity
Cr Services Acquisition Us Llc
A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel Group, Proof-of-concept Study Assessing the Efficacy and Safety of Amlitelimab in Adult Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1226080677
Principal investigator 1 GlaxoSmithKline, LLC. $300.00 03/21/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC DBA CENTRICITY RESEARCH
A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, PLACEBO CONTROLL No dispute reported 06/30/2026 1192100392
Principal investigator 1 GlaxoSmithKline, LLC. $300.00 03/21/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC DBA CENTRICITY RESEARCH
A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, PLACEBO CONTROLL No dispute reported 06/30/2026 1192104088
Principal investigator 1 GlaxoSmithKline, LLC. $4,411.86 03/21/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC DBA CENTRICITY RESEARCH
LONG-TERM EXTENSION STUDY (ATDVANCE) TO EVALUATE THE SAFETY AND EFFICA No dispute reported 06/30/2026 1192110463
Principal investigator 1 SANOFI US SERVICES INC. $288.00 03/17/2025 Non-covered Recipient Entity
Cr Services Acquisition Us Llc
A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel Group, Proof-of-concept Study Assessing the Efficacy and Safety of Amlitelimab in Adult Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1226080673
Principal investigator 1 GlaxoSmithKline, LLC. $3,167.10 02/24/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC DBA CENTRICITY RESEARCH
LONG-TERM EXTENSION STUDY (ATDVANCE) TO EVALUATE THE SAFETY AND EFFICA No dispute reported 06/30/2026 1192101572
Principal investigator 1 GlaxoSmithKline, LLC. $700.00 02/24/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC DBA CENTRICITY RESEARCH
LONG-TERM EXTENSION STUDY (ATDVANCE) TO EVALUATE THE SAFETY AND EFFICA No dispute reported 06/30/2026 1192104420
Principal investigator 1 SANOFI US SERVICES INC. $5,878.60 02/18/2025 Non-covered Recipient Entity
Aventiv Research Columbus
A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel Group, Proof-of-concept Study Assessing the Efficacy and Safety of Amlitelimab in Adult Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1226093928
Principal investigator 1 GlaxoSmithKline, LLC. $34.50 02/05/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC DBA CENTRICITY RESEARCH
A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, PLACEBO CONTROLL No dispute reported 06/30/2026 1192101566
Principal investigator 1 GlaxoSmithKline, LLC. $109.02 02/05/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC DBA CENTRICITY RESEARCH
A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, PLACEBO CONTROLL No dispute reported 06/30/2026 1192104120
Principal investigator 1 GlaxoSmithKline, LLC. $300.00 02/05/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC DBA CENTRICITY RESEARCH
A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, PLACEBO CONTROLL No dispute reported 06/30/2026 1192104432
Principal investigator 1 GlaxoSmithKline, LLC. $231.84 02/05/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC DBA CENTRICITY RESEARCH
A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, PLACEBO CONTROLL No dispute reported 06/30/2026 1192104877
Principal investigator 1 GlaxoSmithKline, LLC. $120.00 02/05/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC DBA CENTRICITY RESEARCH
A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, PLACEBO CONTROLL No dispute reported 06/30/2026 1192110441
Principal investigator 1 GlaxoSmithKline, LLC. $579.60 02/05/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC DBA CENTRICITY RESEARCH
A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, PLACEBO CONTROLL No dispute reported 06/30/2026 1192110480
Principal investigator 1 GlaxoSmithKline, LLC. $60.00 02/05/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC DBA CENTRICITY RESEARCH
A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, PLACEBO CONTROLL No dispute reported 06/30/2026 1192162834
Principal investigator 1 GlaxoSmithKline, LLC. $180.00 02/03/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC DBA CENTRICITY RESEARCH
A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, PLACEBO CONTROLL No dispute reported 06/30/2026 1192101559
Principal investigator 1 GlaxoSmithKline, LLC. $25.00 02/03/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC DBA CENTRICITY RESEARCH
A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, PLACEBO CONTROLL No dispute reported 06/30/2026 1192104871
Principal investigator 1 GlaxoSmithKline, LLC. $50.00 02/03/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC DBA CENTRICITY RESEARCH
A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, PLACEBO CONTROLL No dispute reported 06/30/2026 1192104905
Principal investigator 1 GlaxoSmithKline, LLC. $25.00 02/03/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC DBA CENTRICITY RESEARCH
A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, PLACEBO CONTROLL No dispute reported 06/30/2026 1192105647
Principal investigator 1 GlaxoSmithKline, LLC. $84.00 02/03/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC DBA CENTRICITY RESEARCH
A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, PLACEBO CONTROLL No dispute reported 06/30/2026 1192105662
Principal investigator 1 GlaxoSmithKline, LLC. $579.60 02/03/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC DBA CENTRICITY RESEARCH
A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, PLACEBO CONTROLL No dispute reported 06/30/2026 1192106509
Principal investigator 1 GlaxoSmithKline, LLC. $69.00 02/03/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC DBA CENTRICITY RESEARCH
A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, PLACEBO CONTROLL No dispute reported 06/30/2026 1192106543
Principal investigator 1 GlaxoSmithKline, LLC. $235.98 01/28/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC DBA CENTRICITY RESEARCH
LONG-TERM EXTENSION STUDY (ATDVANCE) TO EVALUATE THE SAFETY AND EFFICA No dispute reported 06/30/2026 1192100384
Principal investigator 1 GlaxoSmithKline, LLC. $44.05 01/28/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC DBA CENTRICITY RESEARCH
LONG-TERM EXTENSION STUDY (ATDVANCE) TO EVALUATE THE SAFETY AND EFFICA No dispute reported 06/30/2026 1192100411
Principal investigator 1 GlaxoSmithKline, LLC. $700.00 01/28/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC DBA CENTRICITY RESEARCH
LONG-TERM EXTENSION STUDY (ATDVANCE) TO EVALUATE THE SAFETY AND EFFICA No dispute reported 06/30/2026 1192101434
Principal investigator 1 GlaxoSmithKline, LLC. $5,364.06 01/28/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC DBA CENTRICITY RESEARCH
LONG-TERM EXTENSION STUDY (ATDVANCE) TO EVALUATE THE SAFETY AND EFFICA No dispute reported 06/30/2026 1192101460
Principal investigator 1 GlaxoSmithKline, LLC. $144.90 01/28/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC DBA CENTRICITY RESEARCH
LONG-TERM EXTENSION STUDY (ATDVANCE) TO EVALUATE THE SAFETY AND EFFICA No dispute reported 06/30/2026 1192104126
Principal investigator 1 GlaxoSmithKline, LLC. $144.90 01/28/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC DBA CENTRICITY RESEARCH
LONG-TERM EXTENSION STUDY (ATDVANCE) TO EVALUATE THE SAFETY AND EFFICA No dispute reported 06/30/2026 1192104454
Principal investigator 1 GlaxoSmithKline, LLC. $144.90 01/28/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC DBA CENTRICITY RESEARCH
LONG-TERM EXTENSION STUDY (ATDVANCE) TO EVALUATE THE SAFETY AND EFFICA No dispute reported 06/30/2026 1192105667
Principal investigator 1 GlaxoSmithKline, LLC. $144.90 01/28/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC DBA CENTRICITY RESEARCH
LONG-TERM EXTENSION STUDY (ATDVANCE) TO EVALUATE THE SAFETY AND EFFICA No dispute reported 06/30/2026 1192110452
Principal investigator 1 GlaxoSmithKline, LLC. $60.00 01/28/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC DBA CENTRICITY RESEARCH
LONG-TERM EXTENSION STUDY (ATDVANCE) TO EVALUATE THE SAFETY AND EFFICA No dispute reported 06/30/2026 1192110469
Principal investigator 1 GlaxoSmithKline, LLC. $144.90 01/28/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC DBA CENTRICITY RESEARCH
LONG-TERM EXTENSION STUDY (ATDVANCE) TO EVALUATE THE SAFETY AND EFFICA No dispute reported 06/30/2026 1192162847
Principal investigator 1 GlaxoSmithKline, LLC. $60.00 01/28/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC DBA CENTRICITY RESEARCH
LONG-TERM EXTENSION STUDY (ATDVANCE) TO EVALUATE THE SAFETY AND EFFICA No dispute reported 06/30/2026 1192162865
Principal investigator 1 SANOFI US SERVICES INC. $6,594.00 01/06/2025 Non-covered Recipient Entity
Aventiv Research Columbus
A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel Group, Proof-of-concept Study Assessing the Efficacy and Safety of Amlitelimab in Adult Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1226093932